BSE Pharma Sector Regulatory Filings — October 27, 2026

Record quarterly One India revenue of INR 3,516 Cr, up 12% YoY, showing domestic franchise strength that partly offsets group-level weakness

North America revenue recovered sequentially to $172 Mn (QoQ improvement) though INR revenue fell 19% YoY to INR 1,643 Cr, signalling a turn that needs confirmation in the next quarter

EBITDA margin contracted from 25.0% to 18.7% YoY (-630 to -720 bps) and PAT fell 35% YoY to INR 878 Cr, outpacing the 27% EBITDA decline and reflecting weak operating leverage

Versus Q1 FY27, revenue rose 4% QoQ, EBITDA margin expanded about 200 bps and PBT grew 8.8% QoQ, indicating the earnings trough may be behind the company

Employee benefits expense rose 12.1% YoY to INR 1,475 Cr while revenue fell about 2%, a key driver of margin erosion that management must address

Other income fell 43.8% YoY to INR 151 Cr and other operating income fell about 75% YoY to INR 36 Cr, removing a cushion beneath reported profit

Q2 FY27 volume growth of 6.2% ahead of IPM's 5.2%, and value growth ex-Tirzepatide of 15.7% vs IPM 14.2%, indicating genuine outperformance beyond the GLP-1 tailwind

FY26 revenue of INR 14,278 Cr with an 18.1% CAGR over FY21-26, supporting a durable growth algorithm

Acquisition debt of about INR 2,500 Cr is targeted for repayment by 2028, subject to schedule and performance; execution here is a balance-sheet watch point

Shareholders approved the MHIL PRSU Scheme 2026 covering up to 73.5 lakh units (~0.76% of paid-up equity), aligning management with long-term performance

EBITDA margin down about 630-720 bps YoY to 18.7% with EBITDA down 27%; the decline is far steeper than the 2% revenue fall, indicating structural cost pressure

PAT down 35% YoY (INR 1,351 Cr to INR 878 Cr) with other income down 44% and other operating income down 75%, so reported profit is increasingly dependent on core operations that are under pressure

Employee benefits up 12.1% YoY to INR 1,475 Cr against a flat-to-declining top line, a persistent cost trend requiring evidence of headcount or productivity action

INR 131 Cr of sales promotion expenses were reclassified into revenue reduction from 1 April 2026 with prior periods restated, so reported revenue growth comparisons are not like-for-like and investors must adjust their models

INR revenue from North America fell 19% YoY and API & Others dropped 59%, showing that US exposure has not yet stabilised despite the sequential recovery

Total debt rose about 50% YoY to INR 699 Cr while trade receivables fell to INR 6,000 Cr from INR 6,902 Cr; the debt build needs to be explained against cash generation

EUR 48 Mn acquisition of a 70% stake in ACTx is payable in tranches, adding integration and cell-therapy development risk to a company whose core is branded generics

Reported Q2 value growth of 14.7% includes Tirzepatide contribution, so a portion of headline momentum is tied to a single therapy and its pricing or supply trajectory

Sequential EBITDA margin expansion of about 200 bps QoQ to 18.7% suggests cost actions may be working; a return toward the mid-20s margin band would imply material PAT upside from the current base

Record INR 3,516 Cr quarterly revenue growing 12% YoY provides a high-visibility, domestic earnings base that can anchor valuation while the export business normalises

Sequential recovery to $172 Mn in North America after a weak YoY period positions the segment for upside if the sequential trend continues into Q3 FY27

Targeted rise of chronic revenue from ~39% to ~50% by FY30E supports margin and visibility improvement, as chronic therapies carry stickier prescription patterns

Volume growth of 6.2% vs IPM 5.2% and ex-Tirzepatide value growth of 15.7% vs IPM 14.2% indicate market share gains that should compound if sustained

The 70% stake in Armed Cell Therapeutics gives early exposure to a high-growth Belgian cell therapy platform at a defined cash outlay (EUR 48 Mn), an asymmetric option if clinical milestones are met

The PRSU scheme and subsidiary-employee grants, approved by shareholders, tie senior and subsidiary talent to performance, supporting hospital-network execution

Cipla's One India (+12% YoY, record INR 3,516 Cr) and Mankind's volume-led domestic growth (6.2% vs IPM 5.2%) show Indian branded businesses carrying sector growth while export and API lines lag (North America -19% YoY in INR, API & Others -59% at Cipla) [implication: favour domestic-weighted pharma]

Cipla's employee benefits rose 12.1% YoY against flat-to-falling revenue, and its EBITDA margin fell 630-720 bps; the pattern signals that wage and talent inflation is outpacing top-line growth at large pharma and may recur across peers [implication: screen peers for operating leverage]

Mankind's reported value growth includes Tirzepatide, and its chronic mix is targeted to rise to ~50% by FY30E, highlighting the shift toward chronic and metabolic therapies as the next volume driver in India [implication: chronic-exposed names warrant a premium]

Mankind's EUR 48 Mn ACTx acquisition signals Indian pharma moving into cell therapy through tranche-based deals that cap early downside [implication: expect more staged M&A in advanced therapeutics]

Cipla's reclassification of sales promotion expenses into revenue reduction, with restated prior periods, underlines that headline revenue comparisons across the sector may be distorted by presentation choices [implication: normalise revenue before comparing peers]

Board refreshment (Cipla's independent director appointment), ESOP/ESAR grants at nominal exercise prices (INR 2), and shareholder-approved PRSU schemes (Max Healthcare) reflect routine but active governance; no insider selling or pledge activity was disclosed in these filings [implication: no governance red flags in the period]

Watch whether EBITDA margin holds above 18.7% and whether employee cost growth moderates from +12% YoY; next earnings date to be confirmed from the company calendar

Sequential recovery to $172 Mn must hold; a reversal would undermine the margin-recovery thesis

Explanation of the ~50% rise in total debt to INR 699 Cr and the decline in trade receivables; watch for working-capital disclosures in the next filing

Shareholder approval of Ms Rashmi Joshi's appointment for the 27 Oct 2026 to 26 Oct 2031 term at the next general meeting

Milestones and tranche payment schedule for the EUR 48 Mn Armed Cell Therapeutics deal and any early clinical or regulatory updates

Progress toward repaying ~INR 2,500 Cr of acquisition debt by 2028, and the chronic-mix shift toward ~50% by FY30E

Monitor pricing, supply, and competitive dynamics for Tirzepatide, since it materially contributes to reported value growth

Board-level grants under the MHIL PRSU Scheme 2026 and CMD remuneration disclosures to follow the 19 Oct 2026 postal ballot outcome